Mizba Baksh
Overview
Explore the profile of Mizba Baksh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
67
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ailawadhi S, Ailawadhi M, Dutta N, Parrondo R, Roy V, Sher T, et al.
Cancer Med
. 2023 Aug;
12(18):19013-19020.
PMID: 37587868
Introduction: Health information technology (HIT) has the potential to improve healthcare delivery and engagement. Studying racial-ethnic disparities in HIT engagement will help understand and overcome challenges to healthcare utilization. Methods:...
2.
Bansal R, Baksh M, Larsen J, Hathcock M, Dingli D, Stewart A, et al.
Blood Cancer J
. 2023 Apr;
13(1):47.
PMID: 37019896
Bone marrow (BM) assessment of minimal residual disease (MRD) is prognostic for survival in multiple myeloma (MM). BM is still hypocellular at month 1 post CAR-T, thus the value of...
3.
Huang K, Dufresne M, Baksh M, Nussbaum S, Abbaszadeh Kasbi A, Mohammed A, et al.
Am Surg
. 2023 Feb;
89(12):5414-5420.
PMID: 36788122
Introduction: Contiguous non-mass enhancement (NME) often coexists with a solid tumor component on MRI, but it can be challenging to predict whether NME represents invasive breast cancer, ductal carcinoma in...
4.
Vivekanandhan S, Bahr D, Kothari A, Ashary M, Baksh M, Gabriel E
Mol Cancer
. 2023 Feb;
22(1):23.
PMID: 36726126
Cancer remains a leading cause of death worldwide, placing a significant burden on healthcare systems as well as the global economy. Rare cancers comprise a group of about 200 cancers...
5.
Baksh M, Mahajan B, Dufresne M, Shoukry M, Nussbaum S, Abbaszadeh-Kasbi A, et al.
Cancer Treat Res Commun
. 2022 Jul;
32:100609.
PMID: 35850075
Background: The new diagnostic concept of liquid biopsy is based on the analysis of circulating tumor cells (CTCs) and cell-free DNA (ctDNA). In addition to providing a more comprehensive view...
6.
Abbaszadeh Kasbi A, Ashary M, Baksh M, Nussbaum S, Attwood K, Gabriel E
Cancer Diagn Progn
. 2022 Apr;
2(1):71-77.
PMID: 35400009
Background/aim: Pancreatic cancer has a very poor prognosis, though outcomes based on age are not well characterized. The aim of current study was to analyze the survival of patients with...
7.
Nussbaum S, Shoukry M, Ashary M, Abbaszadeh Kasbi A, Baksh M, Gabriel E
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326700
The management of cancer has always relied heavily on the imaging modalities used to detect and monitor it. While many of these modalities have been around for decades, the technology...
8.
Baksh M, Li K, Jiang L, Alegria V, Sher T, Roy V, et al.
Clin Case Rep
. 2022 Feb;
10(2):e05329.
PMID: 35140947
Extramedullary multiple myeloma is seen in advanced and aggressive disease and occurs due to plasma cell infiltration of sites other than the bone marrow. Myelomatous ascites or pleural effusion is...
9.
Baksh M, Jiang L, Bhatia U, Alegria V, Sher T, Roy V, et al.
Clin Case Rep
. 2021 Dec;
9(12):e05181.
PMID: 34934497
Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) is often differentiated from myeloma based on the presence of lytic bone lesions (LBL). However, WM/LPL can present with LBL, and management is poorly understood....
10.
Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting
Jayakrishnan T, Aulakh S, Baksh M, Nguyen K, Ailawadhi M, Samreen A, et al.
Cancers (Basel)
. 2021 Nov;
13(22).
PMID: 34830924
Background: Concern exists that the clinical trial populations differ from respective cancer populations in terms of their age distribution affecting the generalizability of the results, especially in underrepresented minorities. We...